Abstract
Despite passage of the Biologics Price Competition and Innovation Act, there are currently only seven biosimilar products on the U.S. market competing with originator brands. Several factors account for the slow development of competition in this market.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
